Concord Biotech announces Board meeting on Sept 23, 2026, to consider bonus shares
Concord Biotech · Pharmaceuticals & Biotechnology
What the filing says
- Board meeting scheduled on Wednesday, September 23, 2026, to consider declaring bonus equity shares
- Declaration subject to shareholders' approval and applicable provisions
- Trading window closed from September 19, 2026, to 48 hours after Board meeting outcome; reopens September 26, 2026
Original filing
Board Meeting Intimation for Meeting To Be Held On Wednesday, September 23, 2026, Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015 Inter-Alia To Consider The Proposal For Declaration Of Bonus Equity Shares To The Existing Equity Shareholders Of The Company
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Concord Biotech
- Dividend / buyback / bonusConcord Biotech approves 1:1 bonus shares issue and share capital increase
Other dividend / buyback / bonus filings this fortnight
- Dividend / buyback / bonusPashupati Cotspin LtdPashupati Cotspin Limited schedules 6th Board Meeting on October 3, 2026
- Dividend / buyback / bonusTransport Corp.Transport Corporation of India Ltd announces subsidiary in China and share buyback
- Dividend / buyback / bonusTransport Corp.Transport Corporation of India approves buyback of shares and China subsidiary
- Dividend / buyback / bonusTransport Corp.Transport Corporation of India approves buyback and China subsidiary incorporation
- Dividend / buyback / bonusTransport Corp.Transport Corporation of India Ltd approves buyback and to incorporate China subsidiary
- Dividend / buyback / bonusTransport Corp.Transport Corporation of India Ltd discloses promoters will not participate in buyback
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.